MedWatch

Demant predicts USD 14m impact of war in Ukraine in first ever quarterly report

Demant has started to publicize quarterly financial results as of today, when it revealed it is maintaining its 2022 guidance despite predicting sanctions on Russia will negatively impact its operating result. (Updated)

Photo: Jens Dresling

(Clarification: The analyst consensus estimates include Demant’s business leg Hearing Implants, whereas the Q1 revenue figures exclude the business unit that Demant recently announced it would divest)

Hearing aid group Demant wants to ”make it easier to compare Demant with similar companies,” leading the 118-year-old firm behind the Bernafon and Oticon brands to start releasing quarterly reports.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs